With its 15 years conference production and management experience, WTG introduces a leading pharma event: "Early Drug Development Summit" in December 3rd-4th 2012 in Berlin, Germany.
The Early Drug Development Summit brings early drug developers together to discuss maximising drug investments, toxicology, safety and biomarkers.
We're pleased to announce that Dr.Lucette Doessegger, Global Head of Translational Safety Medicine at Roche Switzerland, will be sharing her 10 years of industry experience on early drug development at the Early Drug Development Summit on Day 2, 4th December 2012 at 09:15 - 10:00 in Hotel Palace Berlin, Germany.
Dr. Doessegger will discuss "Using Translational Medicines in Early Drug Development", which will cover:
- Designing risk management protocols to understand the mechanism of action and implement safety measurements
- Using translational safety medicine to measure signalling before it reaches clinical trials
- Efficiently determining the impact of toxicity effects on specific populations
Confirmed speakers and their presentations include:
- Dr Andy Parsons, VP Preclinical Development, GSK UK
Developing Business Frameworks for the Successful Co-creation of Value